home
about us
member log-in
contact us

PRODUCTS
MUNICIPAL BONDS
INDEX FUNDS
- Total Asset Fund (TAF)
EVENTS
MARKET RESEARCH

Recent Quotes

View Full List

My Watchlist

Indicators

Markets:

Overview

News

Currencies

International

Treasuries

Roivant Sciences Ltd. - Common Shares (NQ:ROIV)

28.06 -0.49 (-1.72%)

Streaming Delayed Price Updated: 4:00 PM EDT, Mar 13, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Roivant Sciences Ltd. - Common Shares

< Previous 1 2 3 4 5 6 7 8 9 10 Next >

Why Shares of Roivant Sciences Were Down Tuesday ↗

March 21, 2023

After a run-up last week prompted by positive clinical trial results, the stock has given back its recent gains.

Via The Motley Fool

Analyst Expectations for Roivant Sciences's Future ↗

March 16, 2023

Via Benzinga

Roivant Sciences Highlights Topline Data From Atopic Dermatitis Drug In Patients As Young As 2 Years ↗

March 15, 2023

Via Benzinga

The 7 Best Biotech ETFs to Buy for Exposure to the Healthcare Sector ↗

March 15, 2023

To play a permanently relevant industry with the broadest canvas possible, consider acquiring the best biotech ETFs to buy.

Via InvestorPlace

Roivant Reports Positive Topline Results from ADORING 2 Atopic Dermatitis Phase 3 Trial of VTAMA® (tapinarof) Cream, 1% Once Daily in Adults and Children as Young as 2 Years Old

March 15, 2023

From Roivant Sciences

Via GlobeNewswire

Expert Ratings for Roivant Sciences ↗

February 13, 2023

Via Benzinga

Roivant Sciences's Earnings Outlook ↗

February 10, 2023

Via Benzinga

Roivant to Host Investor Call at 8:00 AM ET on Wednesday, March 15 to Review Results from ADORING 2 Phase 3 Trial in Atopic Dermatitis

March 14, 2023

From Roivant Sciences

Via GlobeNewswire

Proteovant Therapeutics to Present Preclinical Data from Estrogen Receptor and IKZF2 Protein Degrader Programs

March 14, 2023

PVTX-321 and PVTX-405 Achieve Development Candidate Nomination

From Roivant Sciences

Via GlobeNewswire

Covant Therapeutics Announces the Formation of its Scientific Advisory Board to Support Platform and Pipeline Advancement

March 07, 2023

From Roivant Sciences

Via GlobeNewswire

Where Roivant Sciences Stands With Analysts ↗

January 19, 2023

Via Benzinga

Roivant Sciences Announces Change to its Board of Directors

February 21, 2023

From Roivant Sciences

Via GlobeNewswire

Immunovant Could Potentially Be An M&A Target, Writes Analyst ↗

February 15, 2023

Via Benzinga

Mixed Signals On Valentine's Day: How Stocks Are Reacting To January Inflation Data ↗

February 14, 2023

Inflation cooled slightly in January, but saw increases in some areas due to the impact of surging food, energy and shelter prices on consumers, the U.S Labor Department said Tuesday.

Via Benzinga

Roivant Sciences Reports Financial Results for the Third Quarter Ended December 31, 2022 and Provides Business Update

February 13, 2023

From Roivant Sciences

Via GlobeNewswire

Earnings Scheduled For February 13, 2023 ↗

February 13, 2023

Companies Reporting Before The Bell • EuroDry (NASDAQ:EDRY) is expected to report quarterly earnings at $2.68 per share on revenue of $21.20 million.

Via Benzinga

Roivant Sciences Announces Pricing of Upsized Public Offering of Common Shares

February 02, 2023

From Roivant Sciences

Via GlobeNewswire

Roivant Sciences Announces Proposed Public Offering of Common Shares

February 01, 2023

From Roivant Sciences

Via GlobeNewswire

Roivant to Report Financial Results for the Third Quarter Ended December 31, 2022 on Monday, February 13, 2023

January 30, 2023

From Roivant Sciences

Via GlobeNewswire

Roivant Touts Encouraging Early Data From Ulcerative Colitis Candidate ↗

January 04, 2023

Via Benzinga

Roivant Announces Statistically Significant and Clinically Meaningful Results from the Induction Period of TUSCANY-2, a Large Global Phase 2b Study of Subcutaneous RVT-3101 for the Treatment of Ulcerative Colitis in Both the Overall and the Biomarker

January 04, 2023

From Roivant Sciences

Via GlobeNewswire

Moderna To Rally Over 42%? Here Are 10 Other Price Target Changes For Monday ↗

December 19, 2022

Morgan Stanley cut VTEX (NYSE: VTEX) price target from $7 to $5. Morgan Stanley analyst Cesar Medina downgraded the stock from Overweight to Equal-Weight. VTEX shares fell 4.9% to close at $3.52 on...

Via Benzinga

Why Roivant Sciences' Shares Are Up Thursday ↗

December 01, 2022

The company is collaborating with Pfizer to create a portfolio company to develop an encouraging drug to treat ulcerative colitis.

Via The Motley Fool

Roivant and Pfizer Form New Vant Company Focused on Developing TL1A Drug Candidate for Inflammatory and Fibrotic Diseases

December 01, 2022

From Roivant Sciences

Via GlobeNewswire

Pinterest To $23? Plus This Analyst Slashes PT On Neoleukin Therapeutics By More Than 90% ↗

November 15, 2022

Rosenblatt raised the price target on Pinterest, Inc. (NYSE: PINS) from $21 to $23. Rosenblatt analyst Barton Crockett maintained a Neutral rating on the stock. Pinterest shares rose 2% to $24.91 in...

Via Benzinga

Intellia Therapeutics To Rally Around 143%? Plus Stifel Cuts PT On This Stock By 94% ↗

November 15, 2022

Chardan Capital boosted the price target on Intellia Therapeutics, Inc. (NASDAQ: NTLA) from $121 to $129. Intellia Therapeutics shares fell 3% to close at $53.30 on Monday.

Via Benzinga

Roivant Sciences Reports Financial Results for the Second Quarter Ended September 30, 2022 and Provides Business Update

November 14, 2022

From Roivant Sciences

Via GlobeNewswire

Affivant to Present Data on AFVT-2101 at 37th Annual Meeting of SITC

November 10, 2022

From Roivant Sciences

Via GlobeNewswire

12 Health Care Stocks Moving In Tuesday's Pre-Market Session ↗

November 08, 2022

Gainers NeuroBo Pharmaceuticals (NASDAQ:NRBO) shares rose 49.1% to $3.22 during Tuesday's pre-market session. The company's market cap stands at $2.8 million.

Via Benzinga

Earnings Scheduled For November 14, 2022 ↗

November 14, 2022

Companies Reporting Before The Bell • Opiant Pharma (NASDAQ:OPNT) is estimated to report quarterly loss at $1.49 per share on revenue of $3.68 million.

Via Benzinga

< Previous 1 2 3 4 5 6 7 8 9 10 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.

Home
About Us
Products
Municipal Bonds
Index Funds
Seminars & Events
Market Research
Contact Us
Member Section
Privacy Policy
Terms & Conditions
Security Notice
Customer Service

Securities offered through Purshe Kaplan Sterling Investments, member FINRA / SIPC, Headquartered at 80 State Street,
Albany, NY 12207
Purshe Kaplan Sterling Investments and Tamar Securities, LLC are not affiliated companies.
Tamar Securities, LLC is a Registered Investment Adviser. Advisory services are only offered to clients or prospective clients where Tamar Securities, LLC
and its representatives are properly licensed or exempt from licensure. Past performance is no guarantee of future returns. Investing involves risk and possible loss of principal capital.
No advice may be rendered by Tamar Securities, LLC unless a client service agreement is in place.

NOT FDIC INSURED. NOT BANK GUARANTEED. MAY LOSE VALUE, INCLUDING LOSS OF PRINCIPAL. NOT INSURED BY ANY STATE OR FEDERAL AGENCY.
Web development by IBCnet.com